89
Participants
Start Date
December 31, 2014
Primary Completion Date
August 31, 2017
Study Completion Date
August 31, 2018
Anti-Thymocyte Globulin (ATG)
Thymoglobulin
Granulocyte colony stimulating factor (GCSF)
Granulocyte colony stimulating factor (GCSF)
Placebo (for ATG)
Normal saline administered by IV infusion to mimic ATG
Placebo (for GCSF)
Placebo prepared to mimic 6mg subcutaneous injection of GCSF
Columbia University-Naomi Berrie Diabetes Center, New York
University of Pittsburgh, Pittsburgh
University of Florida, Gainesville
University of Miami, Miami
University of South Florida Diabetes Center, Tampa
Vanderbilt Eskind Diabetes Clinic, Nashville
Indiana University-Riley Hospital for Children, Indianapolis
University of Minnesota, Minneapolis
Barbara Davis Center, Aurora
Stanford University, Stanford
Benaroya Research Institute, Seattle
University of California - San Francisco, San Francisco
Yale University, New Haven
Collaborators (3)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Center for Research Resources (NCRR)
NIH
Juvenile Diabetes Research Foundation
OTHER
American Diabetes Association
OTHER
Sanofi
INDUSTRY
The Leona M. and Harry B. Helmsley Charitable Trust
OTHER
Amgen
INDUSTRY
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH